Vireo Growth Secures Federal Registrations for Its 41 Florida Medical Dispensaries

Key Facts

Vireo Growth said on November 2 that all 41 of its Florida state-licensed medical cannabis dispensaries had received registrations from the U.S. Drug Enforcement Administration. The move places the company among the beneficiaries of the start of federal registrations for eligible medical facilities, after the Justice Department announced on October 30 that the process had begun. The company said the registrations cover its entire medical network in Florida, according to its statement published via GlobeNewswire. The Justice Department said the initial group includes more than 900 dispensaries in 7 states. The states are Alabama, Florida, Mississippi, South Dakota, Texas, Virginia and West Virginia.

Vireo's registrations came under an order issued in April 2026, but its scope is limited to certain activities eligible for medical cannabis under state licenses. The Justice Department said the Drug Enforcement Administration began with facilities that applied during an initial 60-day period and met federal requirements, including passing a pre-registration investigation. A state-issued license alone is not sufficient to obtain federal registration, according to the department. The program is therefore tied to application reviews and additional federal requirements, alongside local licensing. This process determines how eligible dispensaries enter the initial group of registrations.

Registration requires dispensaries to comply with federal controls on handling controlled substances. The Justice Department said these controls include security, recordkeeping and inventory monitoring, as well as other safeguards. These requirements remain in force for registered facilities as they handle eligible medical cannabis. The department also stressed that the order does not authorize recreational activity. Cannabis activities outside the defined scope remain subject to Schedule I controls, according to its statement.

The order separates registration for certain medical activities from the broader rescheduling of cannabis. The Justice Department said the broader rescheduling proposal is subject to a separate administrative proceeding under the Controlled Substances Act. The dispensaries' federal registrations therefore do not resolve that broader proceeding. The current order remains limited to eligible medical activities and does not cover recreational use. The department's statement confirmed that dispensary registration does not remove the federal compliance requirements that accompany the handling of controlled substances.

The Justice Department announced on October 30 that the initial group includes more than 900 dispensaries across 7 states, including Florida, where Vireo received registrations for its 41 locations. The figure gives a sense of the first phase's scope across states, while the company's announcement represents one group within that program. The department said registrations would continue to be issued in phases to eligible dispensaries. The Drug Enforcement Administration is also reviewing applications from medical cannabis manufacturers and distributors. The department did not set a deadline in its statement for completing those application reviews.

At the company level, Vireo said its third-quarter 2026 results will be released ahead of a conference call scheduled for November 10 at 8:00 a.m. Eastern Time. The timing allows investors to review the results and business strategy updates on the same call, according to the company's statement. A company filing in August said that, assuming completion of all acquisitions announced at the time, it would become the largest cannabis operator in the United States by number of dispensaries, with about 270. The company said in its filing that the FLUENT and C21 deals would expand its retail presence in Florida. It also said the later-announced Planet 13 merger would deepen its position in Florida and Nevada. The expansion figures cited remain contingent on completion of the announced deals, under the assumption set out by the company.